(Q57313773)

PPIB mutations cause severe osteogenesis imperfecta

21 January 2018

1 reference

A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V.

21 January 2018

1 reference

Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation

21 January 2018

1 reference

Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans

21 January 2018

1 reference

Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

21 January 2018

1 reference

Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta

21 January 2018

1 reference

CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta

21 January 2018

1 reference

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

21 January 2018

1 reference

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

21 January 2018

1 reference

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

21 January 2018

1 reference

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

21 January 2018

1 reference

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

21 January 2018

1 reference

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

21 January 2018

1 reference

Adverse effects of bisphosphonates

21 January 2018

1 reference

Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta.

21 January 2018

1 reference

Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates

21 January 2018

1 reference

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

21 January 2018

1 reference